Objective-Levels of serum amyloid A (SAA), an acute-phase protein carried on high-density lipoprotein (HDL), increase in inflammatory states and are associated with increased risk of cardiovascular disease. HDL colocalizes with vascular proteoglycans in atherosclerotic lesions. However, its major apolipoprotein, apolipoprotein A-I, has no proteoglycanbinding domains. Therefore, we investigated whether SAA, which has proteoglycan-binding domains, plays a role in HDL retention by proteoglycans. Methods and Results-HDL from control mice and mice deficient in both SAA1.1 and SAA2.1 (SAA knockout mice) injected with bacterial lipopolysaccharide (LPS) was studied. SAA mRNA expression in the liver and plasma levels of SAA increased dramatically in C57BL/6 mice after LPS administration, although HDL cholesterol did not change. Fast protein liquid chromatography analysis showed most of the SAA to be in HDL. Mass spectrometric analysis indicated that HDL from LPS-injected control mice had high levels of SAA1.1/2.1 and reduced levels of apolipoprotein A-I. HDL from LPS-injected control mice demonstrated high-affinity binding to biglycan relative to normal mouse HDL. In contrast, HDL from LPS-injected SAA knockout mice showed very little binding to biglycan, consistent with SAA facilitating the binding of HDL to vascular proteoglycans.
A therosclerosis is a maladaptive inflammatory response initially to lipoproteins retained in the artery wall. 1, 2 Inflammatory cells, such as T lymphocytes and macrophages, as well as inflammatory cytokines, are detectable in atherosclerotic lesions. 3 In addition, chronically elevated levels of inflammatory proteins, such as high sensitivity C-reactive protein (hs-CRP) and serum amyloid A (SAA), are associated with an increased risk of cardiovascular disease. 4 -9 An independent relationship exists between SAA and future cardiovascular events, similar to that found for hs-CRP. 5 Although SAA was independently but moderately associated with angiographic coronary artery disease, this association was not found for hs-CRP. 5 Whether these proteins have any causal relationship with cardiovascular disease or are simply markers of inflammation remains unclear.
SAA is produced mainly in the liver in response to inflammatory stimuli 10 and is transported in plasma primarily associated with high-density lipoprotein (HDL). 11 Circulating SAA levels increase up to 1000-fold during the acute-phase response following bacterial infection, tissue damage, and acute inflammatory stimuli. 12, 13 More modest elevations are seen in chronic inflammatory conditions, such as obesity, and are associated with an increased risk of cardiovascular disease. 5, 7 Low-density lipoprotein (LDL) and other apolipoprotein (apo) B-and apoE-containing lipoproteins bind to proteoglycans with high affinity because of ionic interactions between positively charged amino acids on apoB and apoE and negatively charged sulfate and carboxylic acid groups on the glycosaminoglycan side chains of proteoglycans. 14, 15 Lipoproteins retained in the arterial intima undergo oxidative and enzymatic modifications, which generate products that can be atherogenic. 16 Because HDL particles do not contain apoB, nor do they normally contain large amounts of apoE, ie, apolipoproteins with positively charged proteoglycan binding domains, HDL should not bind proteoglycans effectively.
ApoA-I, the major HDL apolipoprotein, colocalizes with proteoglycans in atherosclerotic lesions in both mice 17, 18 and humans. 19 Hence it is possible that additional HDL apolipoproteins might target some HDL particles to vascular proteoglycans. Because SAA contains positively charged proteoglycan binding domains, we hypothesized that acute inflammation due to the injection of lipopolysaccharide (LPS) would increase SAA levels and facilitate the binding of SAA-enriched HDL particles to vascular proteoglycans, thus explaining the colocalization of apoA-I with SAA in vascular lesions. The recent availability of SAA knockout (SAAKO) mice 20 allowed us to definitively show a role for SAA in the binding of SAA-containing HDL to vascular proteoglycans.
Methods
Mice C57BL/6J male mice (8 weeks of age) were obtained from the Jackson Laboratory (Bar Harbor, ME) and housed under specific pathogen-free conditions in static microisolator cages. LPS (O111:B4, lot #20137A3) (100 g/mouse) or PBS was administered via intraperitoneal injection, 24 hours before euthanization. After a 4-hour fast, blood was collected, and plasma was prepared immediately. All procedures were performed in accordance with the guidelines for animal welfare of University of Washington, and the protocols were approved by the Animal Welfare Committee of the university.
Mice that lack both major acute-phase SAAs (SAA knockout [SAAKO] mice) 20 were injected with LPS 24 hours before euthanization for preparing HDL from plasma. Wild-type littermates received PBS. These procedures were performed at the University of Kentucky in accordance with the guidelines for animal welfare at that institution. The HDL was then shipped on ice to the University of Washington.
Lipoprotein Preparation
HDL (dϭ1.063 to 1.210 g/mL) was isolated from plasma of control and LPS-injected mice by ultracentrifugation. No SAA was detected in the lipoprotein deficient fraction of plasma. Because apoE can bind to proteoglycans, for proteoglycan binding experiments, apoEcontaining HDL was removed from aliquots of the HDL preparations using an antibody to apoE bound to magnetic beads (Santa Cruz Biotechnology Inc, Santa Cruz, CA). Removal of apoE was con-firmed by immunoblot. Human LDL (dϭ1.019 to 1.063 g/mL) and HDL (dϭ1.063 to 1.210 g/mL) were also isolated from plasma of healthy human volunteers by ultracentrifugation. All lipoproteins were extensively dialyzed against 150 mmol/L NaCl with 1 mmol/L EDTA.
Plasma Levels of Lipids and SAA
Plasma levels of total cholesterol, HDL cholesterol (Genzyme, Cambridge, MA), and triglyceride (Roche, Indianapolis, IN) were determined using enzymatic kits. Plasma levels of SAA were measured by enzyme-linked immunosorbent assay (ELISA) using a goat anti-mouse SAA1 antibody (AF2948, R&D Systems), as described previously. 21, 22 
Real-Time Polymerase Chain Reaction
Please see supplemental material, available online at http://atvb. ahajournals.org, for details of reverse transcription-polymerase chain reaction.
Mass Spectrometric Analysis
Please see supplemental material for details of the mass spectrometric analysis of plasma and HDL. [ 35 S]SO 4 -labeled biglycan synthesized by cultured human aortic smooth muscle cells was interacted with lipoproteins using a gel shift mobility assay as described previously. 23 Additional details of the biglycan isolation and gel mobility shift assay are provided in the supplemental material.
Gel Mobility Shift Assay

Statistical Analysis
Statistical significance was determined by either the Student t tests or ANOVA.
Results
LPS Injection Increases Expression of SAA in Liver and Plasma
SAA mRNA expression in the liver increased dramatically following LPS injection (Supplemental Figure IA) . Conversely, apoA-I mRNA expression was slightly decreased (Supplemental Figure IB) . These results were consistent with our previous observations using cytokines. 24 Plasma SAA also increased dramatically after LPS injection ( Figure 1A ), consistent with the increased mRNA expression in the liver. Plasma levels of cholesterol and triglycerides increased significantly following LPS injection ( Figure 1B and 1D ). However, there were no significant changes in HDL cholesterol levels between control and LPS-injected mice ( Figure  1C ). Very little SAA could be detected by fast protein liquid chromatography and ELISA in association with any lipoprotein particles in control mice (Supplemental Figure IIA) . The increase in cholesterol and triglycerides in the LPS-injected mice was due to an increase in the very-low-density lipoprotein-intermediate density lipoprotein fraction (Supplemental Figure IIB ). The majority of SAA eluted in the HDL particle size range in LPS-injected mice (Supplemental Figure IIB) .
HDL From LPS-Injected Mice Is Enriched in SAA
To evaluate apolipoproteins, HDL from both control and LPS-injected mouse plasma was separated by 10% to 20% gradient SDS-PAGE. SDS-PAGE in conjunction with matrixassisted laser desorption ionization/time of flight (MALDI-TOF) analysis showed that inflammatory HDL had a lower level of apoA-I than control HDL (Figure 2A ). In addition, apoE was increased and SAA was dramatically increased in HDL from LPS-injected mice. Only SAA4, the constitutive isoform of SAA, was detected in control HDL by MALDI- Figure 2 . MALDI-TOF analysis. HDL (dϭ1.063 to 1.210 g/mL) was isolated by ultracentrifugation from plasma of control and LPS-injected mice. HDL (20 g of protein) was separated by SDS-PAGE (10% to 20% gradient gel), and the gel was stained with Coomassie Brilliant Blue. Each gel band corresponding to the apparent molecular weight of SAA1.1/2.1, SAA4, apoA-I, and apoE was cut out and digested with trypsin, and the peptide digest was extracted for tandem mass spectrometric analysis by MALDI-TOF. The arrows indicate bands that were identified by MALDI-TOF and database searching that contained peptides unique to SAA1.1/2.1, SAA4, apoA-I, and apoE (A). Albumin-depleted plasma samples (20 L) from control (B-upper panel) and LPS-injected (B-lower panel) mice were separated by 2-dimensional electrophoresis (first dimension: IEF pH 3 to 10; second dimension: 10% SDS-PAGE), and the gel was stained with a silver stain. Selected spots from 2-dimensional gels were identified by in-gel tryptic digest and MALDI-TOF analysis. The small arrows indicate bands that were identified by tandem mass spectrometry MALDI-TOF and database searching that contained peptides unique to SAA1.1 (small arrow B), SAA2.1 (small arrow A), and apoA-I (B). The spot designated SAA2.1 was identified as such with a MASCOT MOWSE score of 374 (CI 100%) (C), and the adjacent spot was identified as SAA1.1 with a MOWSE score of 403 (CI 100%) (D). *Peaks corresponding to SAA peptides. TOF, whereas most of the SAA in the LPS-injected animals was SAA1.1 and SAA2.1, which are inducible forms of SAA made by the liver. The identification was further confirmed by tandem mass spectrometry of major peaks in each spectrum. To further address the distribution of apoA-I and SAA in HDL particles, plasma from control mice and LPS-injected mice were separated by 2-dimensional electrophoresis before MALDI-TOF analysis ( Figure 2B ). Two-dimensional electrophoresis could separate SAA1.1 ( Figure 2C ) from SAA2.1 ( Figure 2D ) and indicated that both isoforms were increased.
HDL From LPS-Injected Mice Binds Biglycan
HDL-biglycan binding interactions were evaluated by gel mobility shift assay. This assay was performed at pH 7 or 5.5, modeling the pH of normal physiological interactions or that of the acidic microenvironment of the arterial wall, 25 respectively. Whereas human LDL bound to biglycan with high affinity (50% maximal binding at Ϸ0.05 mg/mL) 26 ( Figure  3A) , neither human nor control mouse HDL bound to biglycan even at concentrations up to 3 mg/mL at pH 7 ( Figure 3A ). However, HDL prepared from LPS-injected mice bound to biglycan, with Ϸ80% total biglycan bound at 3 mg/mL HDL ( Figure 3A ). This result was not due to the presence of LPS itself in these particles, as treatment of this HDL with polymixin B did not affect its biglycan-binding properties and addition of LPS to control HDL did not improve its inability to bind to biglycan (data not shown). These results suggest that unlike normal HDL, HDL from LPS-injected mice does have proteoglycan-binding properties at physiological pH.
Recent studies have described lipoprotein-proteoglycan interactions occurring at low pH, modeling the acidic microenvironment of atherosclerotic lesions. 25 Thus, we also evaluated the ability of LDL and HDL to bind to biglycan at pH 5.5. For LDL, Ϸ50% maximal binding was detected at Ϸ0.005 mg/mL at pH 5.5 (versus 0.05 mg/mL at pH 7) ( Figure 3B ). For either human or mouse HDL, Ϸ50% maximal binding was detected at 0.025 to 0.05 mg/mL (versus no binding at up to 3 mg/mL at pH 7) ( Figure 3B ). Thus, both LDL and HDL bind to biglycan with higher affinity at acidic pH than at physiological pH.
SAA Facilitates Binding of HDL to Biglycan
To determine the role of SAA in facilitating the binding of HDL from LPS-injected mice to biglycan, we compared the biglycan-binding ability at pH 5.5 of HDL from SAAKO mice following LPS injection with that of HDL from LPStreated wild-type mice. As expected, SAA levels were undetectable in HDL from LPS-treated SAAKO mice, but SAA was strongly expressed in HDL from LPS-treated wild-type mice ( Figure 4A ). HDL from LPS-treated mice contains some apoE, with SAAKO mice containing less apoE than wild-type mice. The presence of apoE could confound the potential role of SAA in mediating HDL binding to proteoglycans, as a subclass of apoE-containing HDL particles binds to biglycan. 27 Therefore, to determine the effect of SAA independent of apoE, apoE-containing HDL was removed from the preparations using an antibody to apoE bound to magnetic beads before HDL from these mice was subjected to the gel mobility shift assay ( Figure 4A ). ApoE-free HDL from LPS-treated wild-type mice bound biglycan with Ϸ50% maximal binding at 0.25 to 0.5 mg/mL, whereas essentially no proteoglycan binding was detected with HDL from LPStreated SAAKO mice ( Figure 4B and 4C) . Even without removal of the apoE-containing particles, very little biglycan binding was detected using HDL from LPS-injected SAAKO mice (data not shown). The presence of apoE on HDL from LPS-injected wild-type mice increased binding by a maximum of 20%, but the marked difference between binding of HDL from LPS-treated SAAKO mice and LPS-treated wildtype mice was still present (data not shown). These findings thus indicate an important independent role for SAA in Figure 4 . HDL from LPS-injected SAAKO mice does not bind biglycan. A, HDL from wild-type (WT) and SAAKO mice treated with LPS were evaluated for SAA by Western immunoblot analysis. ApoE was removed using an antibody bound to magnetic beads, and preparations of the resulting HDL lacking apoE (HDL-E) were evaluated for apoE content by Western immunoblot analysis. B, Binding of apoE-free HDL from LPS-injected wild-type and SAAKO mice to biglycan was evaluated at acidic pH. A constant amount of biglycan was incubated with no lipoproteins (0), human LDL (0.1 mg/mL), or increasing concentrations of HDL (0 to 1 mg/mL) from LPS-treated wild-type mice or from LPS-treated SAAKO mice and electrophoresed. C, HDL-biglycan binding was quantified as percentage bound using Opti-Quant software (Packard). Representative binding curves are shown.
facilitating the binding of HDL to vascular proteoglycans under inflammatory conditions.
Discussion
SAA is well recognized as an inflammatory marker that is synthesized mainly in the liver and transported through plasma predominantly bound to HDL. Modest elevations of SAA levels, such as are seen in obesity, insulin resistance, and diabetes, 28 -30 are associated with an increased risk of cardiovascular disease. 5, 8, 31 We have previously reported that addition of cholesterol to a high-saturated fat diet increases plasma levels of SAA and accelerates atherosclerosis in LDL receptor-deficient mice independently of its effect on plasma of cholesterol level. 21, 22 In these and other studies, the extent of atherosclerosis correlates with SAA levels and not with circulating lipids and lipoproteins. 21, 22, 31 These findings raise the question of whether SAA might be a mediator rather than a marker of atherosclerosis. In the present study, we demonstrated that SAA levels increase dramatically in HDL after administration of LPS and that SAA facilitates the binding of HDL to the vascular proteoglycan biglycan.
ApoB and apoE bind vascular proteoglycans via ionic interactions between positively charged lysine and arginine residues on the apolipoproteins with negatively charged sulfate and carboxylic acid groups on the glycosaminoglycan side chains of vascular proteoglycans. 14, 15 Once retained in the arterial intima, components of these lipoproteins undergo oxidative modification and modification by enzymes such as secretory phospholipase A2, which generate atherogenic toxic products that can injure the artery wall. 16, 32 The major atherogenic lipoproteins are believed to be apoB-and apoEcontaining lipoproteins, such as LDL, very-low-density lipoprotein, and their remnants, and Lp(a). However, HDL also is present in atherosclerotic lesions in both humans and experimental animals, 18, 33, 34 and we have shown that its major apolipoprotein, apolipoprotein A-I (apoA-I), colocalizes with apoB, apoE, SAA, and proteoglycans in atherosclerotic lesions. [17] [18] [19] 21 Because apoA-I does not have a proteoglycan binding domain, these observations raise the question of whether apolipoproteins such as apoE and SAA might target some HDL particles to be retained by vascular proteoglycans. We have previously demonstrated that the presence of apoE in a subclass of HDL particles can facilitate proteoglycan binding. 27 In this study, we demonstrated that SAA, a HDL apolipoprotein that is increased in inflammatory states, has a similar effect. For this proof of principle study we used LPS to induce large changes in the SAA content of HDL, such that a large percentage of the HDL particles would contain SAA and hence could be tested for proteoglycan binding in a gel shift assay. Much lower levels of SAA are found in both mouse models and human subjects, in whom SAA is associated with atherosclerosis. Nonetheless, retention of even a much smaller number of SAA-containing HDL particles by vascular proteoglycans could, with time, lead to their buildup in the arterial intima.
We used a gel mobility shift assay to demonstrate that SAA-containing HDL binds to biglycan, a vascular proteoglycan that colocalizes with lipoproteins in human atherosclerotic lesions. The recent availability of SAAKO mice 20 allowed us to definitively evaluate the role of SAA in the binding of HDL to proteoglycans after invoking an inflammatory response by injecting LPS. By using HDL from mice deficient in the 2 major circulating inducible isoforms of SAA, we were able to unequivocally demonstrate an important role for SAA in facilitating the binding of HDL to proteoglycans in the inflammatory state. The increased apoE content of HDL in the SAAKO animals after LPS treatment might have contributed to the binding of HDL to biglycan. Therefore, to directly evaluate the role of SAA, we removed apoE-containing HDL particles by immunoaffinity chromatography. HDL particles that did not contain apoE from wild-type mice bound effectively to proteoglycans, particularly at pH 5.5, whereas HDL that was devoid of apoE obtained from LPS-injected SAAKO mice showed negligible proteoglycan binding. These observations provide definitive evidence for a role for SAA in HDL binding to proteoglycans. Even though apoE-containing HDL particles might contribute to HDL retention by vascular proteoglycans in some circumstances, 19, 27 the findings in the present study demonstrate a definitive additional role for SAA. After LPS injection, there is a large abundance of apoA-I relative to apoE in HDL, 35 as confirmed in the present study (see Figure 4 ). From the relative molecular weights of apoA-I and apoE, it can be calculated that only a small percentage of HDL particles contain apoE. However, after LPS injection, the very elevated concentration of SAA in HDL suggests that a considerably higher percentage of HDL particles contain SAA than apoE. These findings are consistent with our observation that removal of apoE-containing HDL particles had a minor effect on their ability to bind biglycan, whereas deficiency of SAA essentially eliminated the ability of HDL to bind proteoglycans.
It was widely believed that SAA can displace apoA-I from HDL particles following inflammatory stimuli. 36, 37 Subsequent studies using adenoviral vector overexpression of SAA in the absence of an acute-phase response indicated that apoA-I levels are not influenced by SAA. 38 Recent data using SAAKO mice unequivocally show that SAA does not affect apoA-I clearance. 20 The reduction in apoA-I and the increase in the SAA content of HDL is thus likely the result of the coordinate and reciprocal regulation by inflammatory cytokines of hepatocytes. 24 Because of the polydispersity of human HDL, it is difficult to estimate the number of apoA-I and SAA particles on acute-phase HDL. Mouse HDL is more homogeneous, with acute-phase particles (9.3 nm) containing 3 apoA-I molecules and 3 to 5 SAA molecules.
ApoA-I does not bind to proteoglycans. The presence of SAA, with its well-characterized proteoglycan binding site, 10 is likely the most important determinant of proteoglycan binding by HDL. This is consistent with our data that indicate that SAA-containing HDL particles bind biglycan with high affinity. Lipoproteins generally bind proteoglycans as a result of interaction of positively charged residues on apolipoproteins with negatively charged residues on the glycosaminoglycan side chains of proteoglycans. Acute-phase SAAcontaining HDL migrates differently on agarose gels to HDL not containing SAA. 20 Interpreting the charge effect that the presence of SAA could have on whole HDL particles is complex because of important compositional changes, partic-ularly relating to lipids. During the acute-phase reaction, HDL is enriched in surface components where, on the other hand, the core cholesteryl ester content is decreased. 20 Such changes in the lipid composition could render oval-shaped particles, which would migrate with a larger Stokes radius in nondenaturing gels. Alternatively, the apolipoproteins could be rearranged on the surface of the HDL so as to migrate as an apparently larger particle. Furthermore, weak SAA interactions with agarose can retard migration in nondenaturing gels. Thus, emphasis should be placed on the proteoglycan binding site of SAA that is critical for amyloid formation. 39 The relevance of this interaction has resulted in it being successfully targeted in therapeutic assault on amyloid formation. 39 The near absence of proteoglycan binding of HDL from LPS-injected SAAKO mice suggests that SAA-containing HDL can be bound and retained by vascular proteoglycans, such as biglycan in humans 19, 40 or perlecan in mice, 17, 18 and that SAA plays a critical role in its binding. These retained HDL particles could then be susceptible to oxidative and enzymatic modifications that render them more atherogenic. 16, 41, 42 For the current studies, we administered LPS to acutely induce a large increase in the SAA content of HDL. Whether similar changes occur with the more modest changes in HDL composition seen in chronic inflammatory states such as obesity remains to be determined. Moreover, some SAA is transported on lipoproteins other than HDL in chronic inflammatory states associated with systemic inflammation, obesity, and insulin resistance 21, 22 or in HDL deficiency states associated with the absence of apoA-I. 43 In these circumstances it is possible that SAA might enhance the proteoglycan binding and vascular retention of apoB and apoE-containing lipoproteins.
In conclusion, inflammatory SAA-containing HDL binds biglycan with high affinity, potentially reducing the atheroprotective functions of HDL and converting it from an antiatherogenic to a proatherogenic lipoprotein.
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